TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Sexually active Chinese women, at risk for pregnancy and not planning to use condoms during trial medication use~* Women in need for contraception and willing to use a hormonal contraceptive method for 13 cycles~* Body mass index ≥18 and ≤29 kg/m\^2~Key Exclusion Criteria:~* Contraindications for contraceptive steroids~* Abnormal cervical smear corresponding to indeterminate changes at screening~* Clinically relevant abnormal laboratory result at screening as judged by the investigator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- ENG-EE (NuvaRing) (Type: EXPERIMENTAL): Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
- DRSP-EE (Type: ACTIVE_COMPARATOR): Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* IPF, diagnosed according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) consensus statement (with or without surgical lung biopsy)~* Pulmonary hypertension, defined as mean pulmonary artery pressure (MPAP) greater than or equal to 25 mm Hg by right heart catheterization (RHC)~Exclusion Criteria:~* Interstitial lung disease due to conditions other than IPF~* Recent lung or upper respiratory tract infection within 4 weeks of study entry~* Acute or chronic impairment other than dyspnea (e.g., angina pectoris, intermittent claudication) limiting the ability to comply with study requirements (e.g., 6-minute walk test)~* Known hypersensitivity to sildenafil~* Known or suspected coronary artery disease (CAD)~* Unstable angina~* Nitrate use~* Known or suspected aortic stenosis (AS)~* Known or suspected heart attack, stroke, or life-threatening arrythmias within 1 month of study entry~* Severe chronic heart failure, defined as New York Heart Association (NYHA) class III/IV and/or left ventricular ejection fraction less than 25%~* Known penile deformities~* Known kidney or liver dysfunction~* Uncontrolled diabetes (blood glucose less than 60 mg/dl or greater than 300 mg/dl)~* Severe serum sodium abnormalities (serum sodium less than 130 mEq/L or greater than 150 mEq/L)~* Condition that may predispose participant to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia)~* Retinitis pigmentosa~* Known or suspected idiopathic hypertrophic subaortic stenosis (IHSS)~* Low blood pressure (systolic blood pressure \[SBP\] less than 100 mm Hg or diastolic blood pressure \[DBP\] less than 50 mm Hg)~* Uncontrolled systemic high blood pressure (SBP greater than 180 mm Hg or DBP greater than 100 mm Hg)~* Cardiopulmonary rehabilitation program started within 8 weeks of study entry or likely to start prior to the conclusion of the study~* Treatment with an endothelin receptor antagonist, iloprost, epoprostenol, inhibitors of CYP3A4 (e.g., cimetidine, erythromycin, ketoconazole, itraconazole, mibefradil), protease inhibitors (e.g., amprenavir, indinavir, or ritonavir), rifampin, alpha-blockers (e.g., doxazosin), or other phosphodiesterase-5 inhibitors~* Current use of alcohol, grapefruit juice, or St. John's wort~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thiamine Supplementation to Improve Cardiac Function in Patients With Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with stable congestive heart failure on a prescription for diuretic drugs~Exclusion Criteria:~* Acute heart failure~* Foreseeable need for further changes in medication~* Current medication containing vitamins~* Patients with a creatinine above 250 μmol/l

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thiamine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject must be willing and able to provide written informed consent.~* Healthy, non-smoking, males and females between the ages of 18 and 55 years of age (inclusive).~* If female, the subject is of non-child bearing potential (i.e., surgically \[bilateral oophorectomy, hysterectomy, or tubal ligation\] or naturally sterile \[\>12 consecutive months without menses\]). Verify by FSH at screening as appropriate.~* Body weight \> 50 kg and BMI between 18 and 30 kg/m2 (inclusive).~* LDL cholesterol ≥ 110mg/dL.~Exclusion Criteria:~* History of thyroid disorder or abnormal thyroid function tests at screening. Repeat testing is allowed once at the discretion of the Investigator. - History of unexplained syncope.~* History of hepatobiliary disease; or AST, ALT or direct bilirubin greater than the upper limit of reference range at screening.~* Positive screening test for HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody.~* Abnormal screening ECG: including machine-read QTc \>450 msec (confirmed by manual over read), QRS \>110 msec, intermittent bundle branch block, frequent premature atrial or premature ventricular contractions, or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant.~* History of sensitivity to a similar study drug (e.g., Karo Bio KB2115 or Metabasis MB7811), or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator.~* History of sensitivity to thyroid medication.~* History of asthma, or intolerance to beta-blockers.~* Use of acetaminophen within 7 days before dosing and throughout the study.~* History of regular use of tobacco or nicotine containing products within the past 6 months.~* Positive urine drug screen or alcohol test at screening or Day -1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- VIA-3196 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Multiple, ascending dosing groups (cohorts) will be evaluated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lentinula Edodes Bars on Dyslipidemia and Oxidative Stress in Cholesterol Individuals: Randomized Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals aged from 20 to 65 years old, of both gender, who had at least one of the following biochemical markers at the borderline level (total cholesterol 180 to 239 mg/dL; LDL 130 to 159 mg/dL; triglycerides of 150 to 200 mg/dL), were recruited, diagnosed by biochemical exams with dates recent to the day of recruitment. The be tolerant to bars ingredients and to Shiitake. Availability to attend the date and time of blood collection.~Exclusion Criteria:~* However, some of them had diseases such as cancer, heart disease, neurodegenerative disease, diabetes, among others. These diseases could be considered as confounders of the study and some recruited people had to be excluded. Pregnant, lactating or hormone replacement women could not participate either.~Individuals were instructed to no change their eating habits and patterns, physical activity level or oral contraceptive use during the study, thus identifying only the effects of Shiitake added to the diet for each individual on the exposed group

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
- Placebo group (Type: PLACEBO_COMPARATOR): Patients with borderline cholesterol consumed two placebo cereal bars for 66 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Overtly healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study~* Are nonsmokers, have not smoked for at least 6 months prior to entering the study~Exclusion Criteria:~* Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study~* Have previously participated or withdrawn from this study~* Had blood loss of more than 450 milliliters (mL) within the last 3 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 (SC Abdomen) (Type: EXPERIMENTAL): Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
- LY900014 (SC Thigh) (Type: EXPERIMENTAL): Single dose of 15-U of LY900014 administered SC into the thigh in one period
- LY900014 (SC Arm) (Type: EXPERIMENTAL): Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
- LY900014 (IV) (Type: ACTIVE_COMPARATOR): Single dose of 15-U of LY900014 administered intravenously (IV) in one period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18- and ≤77-years-old~* Type 2 diabetes~* Taking metformin immediate release (IR) or XR ≥1500 mg for at least 8 weeks as monotherapy~* Glycosylated hemoglobin (A1C) ≥7% and ≤10%~* Body mass index (BMI) ≤40 kg/m2~Exclusion Criteria:~* Women of childbearing potential unable or unwilling to use acceptable birth control~* Women who are pregnant or breastfeeding~* Significant cardiovascular history~* Active liver disease~* Renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 77 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5 mg + Metformin (Type: EXPERIMENTAL): None
- Placebo + Metformin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Definitive diagnosis of CF based on the following:~   * One clinical feature consistent with CF and~  * Either a genotype with 2 identifiable mutations known to cause CF or a sweat chloride concentration \>60 mEq/L by pilocarpine iontophoresis~2. Pancreatic insufficiency documented by a monoclonal faecal elastase (FE) 100 μg/g stool at screening (test results within the previous 12 months are acceptable)~3. Currently receiving pancreatic enzyme replacement therapy~4. Adequate nutritional status based on the following: body mass index (BMI) \>19 kg/m2 in adult subjects or a BMI percentile 10th percentile for age in adolescent (12 to 17 years age group) subjects~5. Are clinically stable with no evidence of concomitant illness or acute upper or lower respiratory tract infection that requires antibiotics during the 7-day interval prior to screening and preceding entry into this clinical study~Exclusion Criteria:~1. Age \<12 years~2. Known contraindication, hypersensitivity, or intolerance to pork or other porcine PEPs~3. Current uncontrolled diabetes mellitus~4. History of solid organ transplantation~5. History of surgery affecting the bowel function and weight gain

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EUR-1008 then Kreon (Type: EXPERIMENTAL): * EUR-1008 during Treatment Period 1 (29 days ±2 days) and~* Kreon during Treatment Period 2 (29 days ±2 days).
- Kreon then EUR-1008 (Type: EXPERIMENTAL): * Kreon during Treatment Period 1 (29 days ±2 days) and~* EUR-1008 during Treatment Period 2 (29 days ±2 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The subject is female and at least 18 years of age.~* The subject is able and willing to complete all procedures and follow-up visits indicated in this protocol.~* The subject has confirmed stress urinary incontinence (SUI) through cough stress test or urodynamics.~* The subject has failed two non-invasive incontinence therapies (such as Kegel exercise, behavior modification, pad use, biofeedback, etc.) for \> 6 months.~Exclusion Criteria:~* The subject has an active urogenital infection or active skin infection in region of surgery.~* The subject has confirmed Pelvic Organ Prolapse (POP) of Stage 2 or higher as determined by POP-Q prolapse grading.~* The subject is having a concomitant pelvic floor procedure.~* The subject has incontinence due to neurogenic causes (e.g. multiple sclerosis, spinal cord/brain injury, cerebrovascular accident, detrusor-external sphincter dyssynergia, Parkinson's disease, or similar conditions).~* The subject had a prior surgical stress urinary incontinence (SUI) treatment.~* The subject has undergone radiation or brachy therapy to treat pelvic cancer.~* The subject has urge predominant incontinence by MESA assessment.~* The subject has an atonic bladder or post void residual (PVR) above 100 cc on ≥ 2 occasions.~* The subject is pregnant and/or is planning to get pregnant in the future.~* The subject has a contraindication to the surgical procedure or the product Instructions for Use (IFU).~* The subject is enrolled in a concurrent clinical trial of any treatment (drug or device) that could affect continence function, without the sponsors approval.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Altis arm (Type: None): Subjects will have an Altis sling placed to treat stress urinary incontinence.
- Comparator arm (Type: None): Subjects will have a transobturator or retropubic sling placed to treat stress urinary incontinence.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Probiotic Supplementation on Endothelial Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 40-75 years old~2. Male sex~3. History of known coronary artery disease (by either history of myocardial infarction, angiogram demonstrative \>=50% stenosis in at least 1 major epicardial coronary artery, or a previous stress test that showed evidence of ischemia that has not been revealed to be a false positive test by angiography)~Exclusion Criteria:~1. Unstable angina or myocardial infarction by history, ECG, and/or enzymatic criteria within 1 month of enrollment.~2. Left ventricular dysfunction as defined by an left ventricular ejection fraction documented as \< 45% within 1 year of enrollment by an echocardiogram, MRI, or nuclear imaging.~3. Uncontrolled hypertension with a blood pressure greater than 170/100 mmHg at the screening visit.~4. Known history of chronic renal insufficiency, liver dysfunction, or cancer besides non-melanoma skin carcinomas or localized prostate cancer requiring systemic treatment within five years of enrollment.~5. Known history of cognitive impairment or inability to follow study procedures~6. Patient with an implanted defibrillator or permanent pacemaker on with the potential participant is known to rely upon for greater than 50% of ventricular depolarizations.~7. Patients who received probiotics, prebiotics, and antibiotics in the last 12 weeks.~8. Patients with dosing changes of vasoactive medications and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the 6 weeks prior to enrollment.

- Gender: MALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GoodBelly Probiotic and Vancomycin (Type: EXPERIMENTAL): Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-site Anesthesia Randomized Controlled STudy of End Tidal Control Compared to Conventional Anesthesia Results

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female 18 years old or greater.~2. Scheduled to undergo general inhaled anesthesia that can be safely exposed to 100% oxygen for up to 2 minutes during general anesthesia.~3. Expected to have airway secured with laryngeal mask airway (LMA) or endotracheal tube.~4. Undergoing a surgical procedure that is anticipated by the investigator to take greater than or equal to 1 hour (operative time measured from induction to cessation of general inhalation anesthetic).~5. American Society of Anesthesiologists (ASA) status classification system I through III:~   1. ASA Physical Status 1 = a normal healthy patient~  2. ASA Physical Status 2 = a patient with mild systemic disease~  3. ASA Physical Status 3 = a patient with severe systemic disease~6. Undergoing intravenous induction.~7. Ability to provide written informed consent.~Exclusion Criteria:~1. Have emergency medical condition requiring surgery.~2. Are female subjects, who are pregnant or lactating.~3. Any subject undergoing cardiac bypass surgery.~4. Any subject undergoing open chest surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Et Control (Type: EXPERIMENTAL): Subjects, meeting the American Society of Anesthesiologists status classification system 1-3, to undergo a surgical procedure with inhaled anesthesia using the investigational Et Control option intervention. For Subjects under the Et Control option, the investigator will use and initiate Et Control after the airway is secured and mechanical ventilation is initiated. Machine log data is collected when the investigator initiates the start of anesthesia case on the Aisys CS2. Adjustments to the anesthesia machine settings, discontinuation of use of the investigational Et Control option, and changes to treatment are based upon clinician judgment for the well being of the subject.
- Control Arm (Type: ACTIVE_COMPARATOR): Subjects, meeting the American Society of Anesthesiologists status classification system 1-3, to undergo a surgical procedure with inhaled anesthesia using conventional fresh gas intervention. For subjects under the conventional option, the investigator will use their conventional means to adjust the vaporizer and mixer, and monitor the patient gas concentrations with the legally marketed Aisys CS2 anesthesia machine without the investigational Et Control feature.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete